GLP1 receptor agonists (e.g., semaglutide) and dual GLP1 receptor agonists/GIP agonists (e.g., tirzepatide) have been shown to significantly reduce weight in patients with obesity, with and without type 2 diabetes
Collagen Protecting Your Skin During Rapid Weight Loss Why it matters: Significant or rapid weight loss, a hallmark of GLP-1 success, can outpace the skin's ability to retract, leading to loose or sagging skin
The Post-GLP-1 Window: A Legal and Effective Category The supplement industry faces a dilemma
And some plans cover Mounjaro for diabetes but not Zepbound for weight loss, which means getting a diabetes-related prescription (if medically appropriate) could change the coverage equation
A company spokesperson says the findings will be disclosed at the end of the study
doi:10.1016/j.dsx.2025.103238 167